Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.36
+0.20000.79%
Post-market: 25.360.00000.00%19:30 EDT
Volume:538.04K
Turnover:13.66M
Market Cap:1.01B
PE:72.09
High:25.57
Open:25.43
Low:25.18
Close:25.16
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.97
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.50
PE(LYR):160.68

Loading ...

Pacira Biosciences Q2 Adjusted Ebitda USD 48.7 Million

THOMSON REUTERS
·
Aug 05

Pacira Biosciences, - Reiterates Fy2026 Exparel Net Product Sales Guidance $600 Mln-$620 Mln

THOMSON REUTERS
·
Aug 05

Will Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative?

Simply Wall St.
·
Aug 02

Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to increase by 4.26%, and institutional views are bullish

Earnings Agent
·
Jul 29

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

GlobeNewswire
·
Jul 28

Pacira Therapeutics: PCRX-201 Progress and Key ASCEND Catalysts Support Buy Rating; $32 Price Target Reaffirmed

TIPRANKS
·
Jul 28

Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone

MT Newswires Live
·
Jul 27

Pacira transitions PCRX-201 to a U.S.-based manufacturing process

TIPRANKS
·
Jul 27

Pacira Transitions Pcrx-201 Gene Therapy to Scalable Commercial Manufacturing Process in Phase 2 Ascend Study

Reuters
·
Jul 27

Pacira Biosciences - Part a Ascend Enrollment Concluded; Topline Data Expected by End of 2026

THOMSON REUTERS
·
Jul 27

Pacira Biosciences Advances Pcrx-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

THOMSON REUTERS
·
Jul 27

Pacira Biosciences to Report Q2 2026 Results, Host Conference Call

Reuters
·
Jul 22

Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued?

Simply Wall St.
·
Jul 08

Pacira Grants Inducement Stock Awards to New Hires, Sets Options Exercise Price at $25.39

Reuters
·
Jul 08

Pacira Biosciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 08

Pacira Biosciences Announces Agreement to Divest Its Iovera° Business to Zimmer Biomet

Reuters
·
Jul 06

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
Jul 01

Pacira Biosciences Price Target Maintained with a $38.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 01

Pacira announces UnitedHealth provides separate reimbursement for Exparel

TIPRANKS
·
Jul 01

Pacira Biosciences Announces Unitedhealthcare NOW Provides Separate Reimbursement for Exparel®

THOMSON REUTERS
·
Jul 01